1. Scrip
  2. >>Business

Vico Therapeutics' RNA Modulators For Neurological Diseases Attract Series A Funding

First Potential Targets Are Spinocerebellar Ataxia And Huntington's Disease

 
• By John Davis

A Netherlands start-up Vico Therapeutics could start clinical trials in late 2021 with its antisense approach to the treatment of rare neurological diseases, financed by its large Series A.

Digital_Human_Brain
• Source: Shutterstock

A new European biotech, Vico Therapeutics, set up just six months ago, has completed a large Series A financing of €27m ($31m) to develop RNA modulators for rare neurological disorders. 

It’s the second large Series A to be announced this week by a northern European biotech, following the closing of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business